What is new in the treatment of multiple sclerosis?

Drugs

Volumn 59, Issue 3, 2000, Pages 401-410

  Weinstock Guttman, Bianca ^a,b   Jacobs, Lawrence D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; GLATIRAMER; GLUCOCORTICOID; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; RECOMBINANT INTERFERON;

ALOPECIA; AMENORRHEA; BONE MARROW SUPPRESSION; BRAIN ATROPHY; CLINICAL TRIAL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HEMORRHAGIC CYSTITIS; HUMAN; LEUKOPENIA; LIVER TOXICITY; MULTIPLE SCLEROSIS; MYOCARDITIS; NAUSEA; RELAPSE; REVIEW; URINARY TRACT INFECTION;

EID: 0034048650     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059030-00002     Document Type: Review

References (43)

1. 1. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993: 655-61
2. 2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94
3. 3. Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352 (9139): 1498-504
4. 4. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11
5. 5. Lucchinetti CF, Bruck W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996; 6: 259-74
6. 6. Trap BD, Peterson J, Ransohoff RM, et al. Axonal transaction in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85
7. 7. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, et al. The interferons: biological effects mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995; 37: 7-15
8. 8. Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanism of action. Neurology 1998; 51: 682-9
9. 9. Runkel L, Meier W, Pepinsky B, et al. Structural analysis of human interferon beta (IFNβ): studies addressing the activity differences between IFNβ-1a and IFNβ-1b [abstract P203]. Mult Scler 1997; 3: 337
10. 10. Alam J, McAllister A, Scaramucci J, et al. Pharmacokinetics and pharmacodynamics of interferon beta-1a in healthy volunteers after intravenous, subcutaneous and intramuscular administration. Clin Drug Invest 1997; 14 (1): 35-43
11. 11. Munafo A, Trinchard-Lugan I, Nguyen TXQ, et al. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 1998; 5: 187-93
12. 12. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76
13. 13. The IFNB Multiple Sclerosis Study Group, the UBC MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85
14. 14. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon-β-1a for relapsing multiple sclerosis. Ann Neurol 1998; 43: 79-87
15. 15. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7
16. 16. Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS: Multiple Collaborative Research Group. Neurology 1999; 53 (8): 1698-704
17. 17. Bornstein MB, Miller AI, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317: 408-14
18. 18. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability: Copolymer I Multiple Sclerosis Study Group. Neurology 1998; 50 (3): 701-8
19. 19. Comi G, Filippi M, the Copaxone MRI study group. The effect of glatiramer acetate (Copaxone®) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis: a multi-center randomized, double-blind placebo-controlled study extended by open-label treatment. Neurology 1999; 52: A289
20. 20. Fazekas F, Deisenhammer F, Strasser FS, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis: Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349: 589-93
21. 21. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998; 50: 398-402
22. 22. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273-81
23. 23. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 38: 1051-5
24. 24. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51: 1219-20
25. 25. Morcau T, Blanc S, Riche G, et al. ERAZISMUS: Early Azathioprine versus Beta-Interferon Treatment in Multiple Sclerosis: results of a pilot safely study [abstract]. The 9th Annual Meeting of the European Neurological Society: 1999 Jun 5-9; Milan, 143
26. 26. Goodkin DE, Rudick RA, VanderBrug Medendorp S, at al. Low-dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30-40
27. 27. Hartung HP, Gonsette R, the MIMS-Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomized, observer-blind phase III trial: clinical results and three-year follow-up [abstract]. Neurology 1999; 52: A290
28. 28. Sipe JC, Romine JS, Zozloi JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13
29. 29. Patty D. Results of the 3-year, double blind, placebo-controlled study of interferon beta 1a (Rebif) in secondary-progressive multiple sclerosis. The 9th Annual Meeting of the European Neurological Society: 1999 Jun 5-9; Milan
30. 30. Goodkin DK, Rudick RA, VanderBrug Medendorp S. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analysis of serial MRIs. Neurology 1996; 47: 1153-7
31. 31. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 1983; 308: 173-80
32. 32. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43 (5): 910-8
33. 33. The Canadian Cooperative Multiple Sclerosis Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441-6
34. 34. Weinstock-Guttman B, Kinkel RP, Cohen JA, et al. Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. Neurologist 1997; 3: 178-85
35. 35. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244: 153-9
36. 36. Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999; 111: 35-44
37. 37. Rovaris M, Filippi M, Mastronardo G, et al. Assessment of Mylinax™ (cladribine) in patients with progressive MS: subgroup analysis of a phase III multicenter trial [abstract]. Neurology 1999; 52: A291
38. 38. Durelli L, Cocito D, Riccio A. High dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986; 36: 238-43
39. 39. Andersson PB, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J Neurol Sci 1998; 160: 16-25
40. 40. Barnes D, Hughes RAC, Morris R, et al. Randomized trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902-6
41. 41. Beck RW, Cleary PA, Trobe J, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329: 1764-9
42. 42. Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998; 51: 239-45
43. 43. US MS society urges early drug treatment. Scrip 1998 Oct 23; 2381: 21